Pharmacokinetics of MK4305 in Patients With Hepatic Insufficiency
This study has been completed.
Sponsor:
Merck
Information provided by:
Merck
ClinicalTrials.gov Identifier:
NCT01043926
First received: January 5, 2010
Last updated: May 26, 2010
Last verified: May 2010
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This study will determine whether the plasma concentration-time profile and pharmacokinetics of MK4305 in patients with moderate and mild hepatic insufficiency are similar to those observed in healthy patients.
| Condition | Intervention | Phase |
|---|---|---|
|
Insomnia Hepatic Insufficiency |
Drug: MK4305 |
Phase 1 |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Endpoint Classification: Pharmacokinetics Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | A Single Dose Study to Investigate the Pharmacokinetics of MK4305 in Patients With Hepatic Insufficiency |
Further study details as provided by Merck:
Primary Outcome Measures:
- Area under the plasma concentration versus time curve (AUC) in patients with moderate hepatic insufficiency compared to that in healthy subjects [ Time Frame: Up to 144 hours post dose ] [ Designated as safety issue: No ]
- Area under the plasma concentration versus time curve (AUC) in patients with mild hepatic insufficiency compared to that in healthy subjects [ Time Frame: Up to 144 hours post dose ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- Safety and tolerability of MK4305 measured by the number of clinical and laboratory adverse events [ Time Frame: Through 14 days after administration of study drug ] [ Designated as safety issue: Yes ]
| Enrollment: | 16 |
| Study Start Date: | February 2010 |
| Study Completion Date: | April 2010 |
| Primary Completion Date: | April 2010 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Part I: Arm A
Patients with moderate hepatic insufficiency
|
Drug: MK4305
Single oral dose of 20 mg MK4305 on Day 1 after an overnight fast with water
|
|
Experimental: Part I: Arm B
Healthy subjects to match patients with moderate hepatic insufficiency
|
Drug: MK4305
Single oral dose of 20 mg MK4305 on Day 1 after an overnight fast with water
|
|
Experimental: Part II: Arm C
Patients with mild hepatic insufficiency
|
Drug: MK4305
Single oral dose of 20 mg MK4305 on Day 1 after an overnight fast with water
|
|
Experimental: Part II: Arm D
Healthy subjects to match patients with mild hepatic insufficiency
|
Drug: MK4305
Single oral dose of 20 mg MK4305 on Day 1 after an overnight fast with water
|
Detailed Description:
Study Design:
If there is no significant difference in the pharmacokinetics of MK4305 between healthy subjects and moderate hepatic insufficiency patients in Part I of the study, then the study will not continue into Part II.
Anticipated Sample Size:
32 (16 in each Part: 8 healthy and 8 patients)
Eligibility| Ages Eligible for Study: | 18 Years to 65 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria for Hepatic Insufficiency Patients:
- Females of reproductive potential must have a negative pregnancy test and agree to use two methods of birth control
- Body Mass Index (BMI) <=35 kg/m prior to start of study
- Diagnosis of stable hepatic insufficiency
- Smoking is restricted to <= 10 cigarettes per day
Inclusion Criteria for Healthy Matched Subjects:
- Females of reproductive potential must have a negative pregnancy test and agree to use two methods of birth control
- BMI within approximately 20% of that of his/her hepatic subject
- Healthy subject
- Subject is matched by race, gender, age (+/- 5 yrs) to his/her hepatic subject enrolled in the study
Exclusion Criteria for Hepatic Insufficiency Patients:
- Patient is mentally or legally incapacitated
- History of a clinically significant psychiatric disorder over the last 5 to 10 years
- Patient has a history of any illness not related to his/her hepatic insufficiency
- History of a persistent sleep abnormality occurring for three (3) months
- Patient has a history of stroke, chronic seizures, or major neurological disorder
- History of clinically significant hematological, immunological, renal, respiratory, or genitourinary abnormalities, uncomplicated kidney stones or childhood asthma
- History of cancer
- History of cataplexy
- Patient is a nursing mother
- Patient consumes more than 3 servings of alcohol a day
- Caffeine consumption should be limited to <= then 6 servings a day
- History of multiple and/or severe allergies
- Patient is currently using or has history of illegal drug use
- Patient has a history of any chronic and/or active hepatic disease
- Patient has traveled across 3 or more time zones
- Patient works a night shift and is not able to avoid night shift work within 1 week before each treatment visit
Exclusion Criteria for Healthy Matched Subjects:
- Subject is mentally or legally incapacitated. History of a clinically significant psychiatric disorder over the last 5 to 10 years.
- Subject has a history of any illness
- History of a persistent sleep abnormality occurring for three (3) months
- Subject has a history of stroke, chronic seizures, or major neurological disorder
- History of clinically significant hematological, immunological, renal, respiratory, or genitourinary abnormalities, uncomplicated kidney stones or childhood asthma
- History of cancer
- History of cataplexy
- Subject is a nursing mother
- Subject consumes more than 3 servings of alcohol a day
- Caffeine consumption should be limited to <= then 6 servings a day
- History of multiple and/or severe allergies
- Subject is currently using or has history of illegal drug use
- Subject has a history of any chronic and/or active hepatic disease
- Subject has traveled across 3 or more time zones
- Subject works a night shift and is not able to avoid night shift work within 1 week before each treatment visit
Contacts and Locations
More Information
No publications provided
| Responsible Party: | Executive Vice President, Clinical and Quantitative Sciences, Merck Sharp & Dohme Corp |
| ClinicalTrials.gov Identifier: | NCT01043926 History of Changes |
| Other Study ID Numbers: | 2010_500, MK4305-017 |
| Study First Received: | January 5, 2010 |
| Last Updated: | May 26, 2010 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by Merck:
|
Hepatic Insufficiency |
Additional relevant MeSH terms:
|
Hepatic Insufficiency Liver Diseases Digestive System Diseases |
ClinicalTrials.gov processed this record on June 18, 2013